Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Gold Nanomedicine Clinical Trial Delivers Promising Results

Abstract:
Novel Approach in Cancer Therapy at the Forefront of Gold-Based Medical Applications

Gold Nanomedicine Clinical Trial Delivers Promising Results

London | Posted on December 24th, 2010

The World Gold Council (WGC) is delighted with the successful phase 1 clinical trial of a unique nanomedicine that uses nanoparticles of gold as the core of a delivery system for tumour targeted drug delivery. The research, published in the current edition of Clinical Cancer Research, was carried out by US-based life sciences company CytImmune Sciences Inc.

CytImmune's technology is at the forefront of a raft of gold-based innovations as described earlier this year by the WGC in a paper entitled 'Gold for Good: Gold and nanotechnology in the age of innovation'. The report demonstrates how gold nanoparticles exhibit a variety of unique properties which are showing great potential in a range of fields.

Dr Richard Holliday, Director, Technology at the WGC said: "Gold has a long history in the biomedical field, being the material of choice in many diagnostic platforms and a key constituent for rheumatoid arthritis treatment. The dawn of the 'nano-age' has further broadened the potential of gold in biomedical applications and it is exciting to see the outcome of this clinical trial which suggests that gold can act as an effective and safe drug delivery system."

In medicine, gold nanoparticles can serve as a simple, elegant platform upon which potent therapies may be bound. In this clinical trial the nanoparticles, which were coated with both an immune-avoiding molecule and a potent anti-cancer agent, were shown to be very well tolerated and to target solid tumours. There is hope that such targeting technology will be effective against a range of cancers, including lung, pancreatic, breast and ovarian cancer.

Dr Lawrence Tamarkin, CEO of CytImmune Sciences Inc. said: "This phase 1 clinical study potentially marks the beginning of a new strategy in cancer treatment where gold nanoparticle-based cancer therapeutics are used first, before surgery, to reduce tumour burden. Reducing tumour size may require less sophisticated surgeries to remove any residual tumour, leading to shorter hospital stays and to improved patient outcomes. Phase 2 clinical studies will prove the value of this novel drug delivery platform."

Dr Holliday continued: "By continuously reviewing and monitoring the global research landscape in gold science and technology, we are able to identify and, where appropriate, help accelerate the time to market key, new technologies that have social, environmental or medical benefits."

####

For more information, please click here

Copyright © World Gold Council

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Gold nanoparticle chains confine light to the nanoscale October 31st, 2014

'Nanomotor lithography' answers call for affordable, simpler device manufacturing October 31st, 2014

Device invented at Johns Hopkins provides up-close look at cancer on the move: Microscopic view of metastasis could give insight about how to keep cancer in check October 31st, 2014

Possible Futures

Imaging electric charge propagating along microbial nanowires October 20th, 2014

Superconducting circuits, simplified: New circuit design could unlock the power of experimental superconducting computer chips October 18th, 2014

Nanocoatings Market By Product Is Expected To Reach USD 8.17 Billion By 2020: Grand View Research, Inc. October 15th, 2014

Perpetuus Carbon Group Receives Independent Verification of its Production Capacity for Graphenes at 140 Tonnes per Annum: Perpetuus Becomes the First Manufacturer in the Sector to Allow Third Party Audit October 7th, 2014

Nanomedicine

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Production of Biocompatible Polymers in Iran October 30th, 2014

Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014

'Electronic skin' could improve early breast cancer detection October 29th, 2014

Announcements

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Gold nanoparticle chains confine light to the nanoscale October 31st, 2014

'Nanomotor lithography' answers call for affordable, simpler device manufacturing October 31st, 2014

Device invented at Johns Hopkins provides up-close look at cancer on the move: Microscopic view of metastasis could give insight about how to keep cancer in check October 31st, 2014

Nanobiotechnology

Tiny carbon nanotube pores make big impact October 29th, 2014

Molecular beacons shine light on how cells 'crawl' October 27th, 2014

Breakthrough in molecular electronics paves the way for DNA-based computer circuits in the future: DNA-based programmable circuits could be more sophisticated, cheaper and simpler to make October 27th, 2014

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE